Sun Pharma’s quarterly profit drops sharply in the latest results, with outlets attributing the decline to one-time or “exceptional” charges. The Hindu reports a 36% plunge in Q2 profit despite revenue growth, noting that excluding exceptional items, adjusted net profit is ₹3,162 crore.
Business Line - Home similarly highlights that Sun Pharma posts a lower quarterly profit, pointing to a one-time charge linked to an acquisition. It says consolidated net profit falls to ₹1,989 crore for the quarter ended September 30, compared with ₹3,118 crore a year earlier.
Together, the coverage focuses on how non-recurring items drive the year-on-year profit decline, while the underlying performance is framed differently: The Hindu stresses adjusted profitability after removing exceptional charges, while Business Line - Home emphasises the specific acquisition-related nature of the charge.